BIOMÉRIEUX

Assess the Risk of AKI. Two Biomarkers. One AKIRISK™ Score.

VIDAS® NEPHROCHECK®

[TIMP-2 • IGFBP-7]

FDA-cleared to aid in the risk assessment of acute kidney injury (AKI).[1]

VIDAS NEPHROCHECK Test Results*	What It Means
Negative AKIRISK Score ≤ 0.3	Patient is at lower risk of developing moderate to severe AKI within 12 hours of evaluation
Positive AKIRISK Score > 0.3	Patient could develop moderate to severe AKI within 12 hours of evaluation

*Should not be used as a standalone test. Test result must be evaluated with other clinical laboratory test information.

Intended Use[1]

The VIDAS NEPHROCHECK assay is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and or respiratory compromise and are ICU patients as an aid in the risk assessment for moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment. The VIDAS NEPHROCHECK test is intended to be used in patients 21 years of age or older.

VIDAS NEPHROCHECK is an automated test for use on the VIDAS 3 instrument.

SCAN FOR ADDITIONAL INFORMATION

Know Earlier. Intervene Sooner. Avoid AKI.

VIDAS® NEPHROCHECK®

[TIMP-2 • IGFBP-7]

Now available on VIDAS® 3.



VIDAS ACUTE AND CRITICAL CARE PANELS

- NEPHROCHECK®
- B·R·A·H·M·S PCT™
- D-Dimer Exclusion™ II

The addition of the NEPHROCHECK assay onto the VIDAS 3 platform is complementary to other tests (like PCT) that can be run concurrently to detect sepsis, which is a significant risk factor for AKI.

Assess the Risk of Acute Kidney Injury (AKI)

VIDAS® NEPHROCHECK®
[TIMP-2 • IGFBP-7]



Asymptomatic – Risk Assessment
[TIMP-2 • IGFBP-7]*

*Tissue Inhibitor of Metalloproteinase-2
Insulin-like Growth Factor Binding Protein-7

Symptomatic – Diagnostic
Serum Creatinine, Urine Output

- Non-diagnostic for ~48 – 72 hours
- sCr elevated after 50% of function loss[2]

Know Earlier. Intervene Sooner. Avoid AKI.

VIDAS® NEPHROCHECK®
[TIMP-2 • IGFBP-7]

Use of KDIGO care bundle can significantly reduce AKI severity[3]

Kidney Disease Improving Global Outcomes (KDIGO) consensus recommends early intervention to decrease the risk of Stage 2 (moderate) and Stage 3 (severe) AKI.

KDIGO recommends the following for patients identified as high risk:

- Discontinuing nephrotoxins or changing dosage
- Volume status & perfusion pressure
- Hemodynamic monitoring
- Monitoring frequency of serum creatinine and urine output
- Avoid hyperglycemia
- Consider alternatives to radiocontrast agents

1. VIDAS NEPHROCHECK Package Insert 057209-01-2022-07
2. Mårtensson J. Brit J Anaesth. 2012;109(6):843-850
3. KDIGO. Kidney Inter, Suppl. 2012;2:1-138.